MDT-AP-2900
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- S1
- umap1_2d
- -0.739586113
- umap2_2d
- -11.35244363
- umap1_3d
- -3.137045592
- umap2_3d
- 0.149684444
- umap3_3d
- 5.418145006
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- ALLOGRAFT_REJECTION+0.480
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.470
- INFLAMMATORY_RESPONSE+0.440
- COAGULATION+0.370
- COMPLEMENT+0.360
- IL6_JAK_STAT3_SIGNALING+0.360
- KRAS_SIGNALING_UP+0.290
- ANDROGEN_RESPONSE+0.240
Top 10 suppressed
- DNA_REPAIR-0.330
- MYC_TARGETS_V2-0.260
- OXIDATIVE_PHOSPHORYLATION-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.220
- WNT_BETA_CATENIN_SIGNALING-0.190
- MITOTIC_SPINDLE-0.170
- UNFOLDED_PROTEIN_RESPONSE-0.160
- CHOLESTEROL_HOMEOSTASIS-0.140
- UV_RESPONSE_UP-0.140
- E2F_TARGETS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1B1-01A-21R-A12P-07 | — | A | 0.868 |
| 2 | f26d1599-6e75-4c0d-8b40-c7e45fe9da76 | — | — | 0.866 |
| 3 | SRR934794 | — | — | 0.865 |
| 4 | MDT-AP-2658 | Med | Medulloblastoma | 0.838 |
| 5 | MDT-AP-2921 | Med | Medulloblastoma | 0.837 |
| 6 | MDT-AP-2936 | Med | Medulloblastoma | 0.833 |
| 7 | BS_02NZT8CE | low-grade glioma | — | 0.832 |
| 8 | MDT-AP-3277 | Med | Medulloblastoma | 0.830 |
| 9 | MDT-AP-0363 | Med | Medulloblastoma | 0.829 |
| 10 | R323 | — | — | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |